Stockscreener 앱 받기
0.3487
9.10%
-0.0349
시간 외 거래:
.35
0.0013
+0.37%
전일 마감가:
$0.3836
열려 있는:
$0.36
하루 거래량:
1.26M
Relative Volume:
1.25
시가총액:
$17.72M
수익:
$65.27M
순이익/손실:
$-19.15M
주가수익비율:
-0.5617
EPS:
-0.6208
순현금흐름:
$-12.43M
1주 성능:
+4.40%
1개월 성능:
+1.13%
6개월 성능:
-66.79%
1년 성능:
+9.79%
1일 변동 폭
$0.3303
$0.3623
1주일 범위
$0.29
$0.45
52주 변동 폭
$0.2805
$1.32
Cosmos Health Inc Stock (COSM) Company Profile
명칭
Cosmos Health Inc
전화
312-536-3102
주소
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Compare COSM vs MCK, COR, CAH, HSIC, AHG
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COSM
Cosmos Health Inc
|
0.3487 | 19.50M | 65.27M | -19.15M | -12.43M | -0.6208 |
MCK
Mckesson Corp
|
842.25 | 105.22B | 397.96B | 4.55B | 9.64B | 34.77 |
COR
Cencora Inc
|
312.39 | 62.84B | 325.78B | 1.64B | 3.61B | 8.3139 |
CAH
Cardinal Health Inc
|
204.92 | 49.69B | 244.67B | 1.68B | 5.51B | 6.9487 |
HSIC
Henry Schein Inc
|
78.84 | 9.08B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
1.98 | 1.69B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cosmos Health Inc 주식(COSM)의 최신 뉴스
Cosmos Health Introduces the "18 Series" in the United StatesA Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products - ACCESS Newswire
This supplement line only launches products at exact clinical-trial doses - Stock Titan
Cosmos Health to begin Liv18 liver supplement production in April By Investing.com - Investing.com India
Cosmos Health to begin Liv18 liver supplement production in April - Investing.com
Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Produ - ACCESS Newswire
A U.S.-made liver supplement is central to Cosmos Health's $5M push - Stock Titan
COSM earnings show rapid revenue growth - MSN
Cosmos Health (COSM) Unveils Innovative Curcumin Supplement for U.S. Market - GuruFocus
Cosmos Health expands AI integration across operations By Investing.com - Investing.com Australia
Cosmos Health plans Q2 U.S. launch of curcumin supplement - Investing.com
Cosmos Health Continues US Expansion with Q2 Launch of Cur18a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health - ACCESS Newswire
Cosmos Health plans Q2 U.S. launch of curcumin supplement By Investing.com - Investing.com UK
Trending Industry Today: Cosmos Health Leads Gains In ETH-Holding Companies Stocks - Moomoo
Form 4Statement of changes in beneficial ownership of securities - ADVFN
COSM Stock Price, Quote & Chart | COSMOS HEALTH INC (NASDAQ:COSM) - ChartMill
Cosmos Health expands AI integration across operations - Investing.com
Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30% - ACCESS Newswire
Record 2025 revenue and margin expansion at Cosmos Health (COSM) - Stock Titan
Cosmos Health Inc. 2025 Annual Report: Growth Strategy, Product Portfolio, and Global Healthcare Market Expansion - Minichart
Cosmos Health (COSM) Achieves Record Revenue and Significant Mar - GuruFocus
Cosmos 2025 10-K: $65.3M Revenue, $(0.63) EPS on net loss - TradingView
Cosmos Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cosmos Health (NASDAQ: COSM) expands pipeline, AI drug repurposing and equity funding - Stock Titan
Cosmos Health reports record revenue of $65.3 million in 2025 By Investing.com - Investing.com South Africa
Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Con - ACCESS Newswire
Cosmos Health reports record revenue of $65.3 million in 2025 - Investing.com
Cosmos Health receives third UAE order for 60,000 units By Investing.com - Investing.com Australia
Cosmos Health receives third UAE order for 60,000 units - Investing.com
Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units - ACCESS Newswire
A third UAE reorder lifts Cosmos Health product demand to 270,000 units - Stock Titan
Cosmos Health sees strong growth, unaffected by Middle East tensions - MSN
Cosmos Health reports no material impact from Middle East conflict By Investing.com - Investing.com Australia
Cosmos Health Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView — Track All Markets
Cosmos Health (COSM) Reports Strong Performance Amid Middle East Tensions - GuruFocus
Cosmos Health reports no material impact from Middle East conflict - Investing.com
Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months - Bitget
Market Outlook: Is Cosmos Health Inc part of any major indexEarnings Growth Report & AI Forecasted Stock Moves - baoquankhu1.vn
Cosmos Health plans Q2 U.S. launch of liver supplement Liv18 By Investing.com - Investing.com Australia
COSM Prepares for Q2 U.S. Launch of Liv18, Its Advanced Liver He - GuruFocus
Cosmos Health plans Q2 U.S. launch of liver supplement Liv18 - Investing.com
Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18a Clinically Proven, Patented Supplement for Liver Fat Reduction - ACCESS Newswire
Liver fat affects 30% of U.S. adults. Cosmos plans Q2 Liv18 launch - Stock Titan
Cosmos Health Inc (COSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
9.88%
4.09%
자본화:
|
볼륨(24시간):